FIRM FIXED PRICESMALL BUSINESS SET ASIDE - TOTAL

PROTEIOS TECHNOLOGY, INC. - SBIR PHASE II, TOPIC 429: A NEW PARADIGM FOR AUTOLOGOUS AND ALLOGENEIC CELL THERAPY MANUFACTURING

PIID: 75N91023C00028Solicitation ID: PHS 2023-1

Signed Date: Dec 11, 2025Effective Date: Sep 15, 2023End Date: Closed on Feb 16, 2026

Award $

$2.0M

Vendor

PROTEIOS TECHNOLOGY, INC.

NAICS

541715

Signed Date

Dec 11, 2025

Key Details

Dollars Obligated

$2.0M

Base & All Options

Awarding Agency

Awarding Sub-Agency

National Institutes of Health

NAICS Code

Product Service Code

AN12 - HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH

Extent Competed

FULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES

Number of Offers

Place of Performance

ISSAQUAH, WA, 980275621, CD-WA-08

SBIR PHASE II, TOPIC 429: A NEW PARADIGM FOR AUTOLOGOUS AND ALLOGENEIC CELL THERAPY MANUFACTURING

On Dec 11, 2025, Department of Health and Human Services obligated $2,049,979 to PROTEIOS TECHNOLOGY, INC. for sbir phase ii, topic 429: a new paradigm for autologous and allogeneic cell therapy manufacturing. The award is classified under NAICS 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) and issued as a firm fixed price contract. Competition extent: full and open competition after exclusion of sources with 2 offers received. The procurement used a SMALL BUSINESS SET ASIDE - TOTAL set-aside. Performance is located in ISSAQUAH, WA.